venBio Partners LLC
An institutional investment manager in SAN FRANCISCO, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1776382.
- Reported value$519.4m
- Positions7
Holdings: 7 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Pharvaris N V | COM | N69605108 | 161 | 30.9% | 4,643,430 | Added+4,126 | |
| Parabilis Medicines IncPBLS | COM | 698955101 | 144 | 27.8% | 5,266,697 | New+5,266,697 | |
| Alumis IncALMS | COM | 022307102 | 127 | 24.5% | 4,528,408 | Unchanged | |
| Achieve Life Science IncACHV | COM | 004468500 | 38.6 | 7.4% | 5,914,720 | New+5,914,720 | |
| ALX Oncology Holdings IncALXO | COM | 00166B105 | 26.7 | 5.1% | 12,884,638 | Unchanged | |
| Harmony Biosciences Holdings inHRMY | COM | 413197104 | 17.2 | 3.3% | 472,194 | Reduced−17,000 | |
| Lyell Immunopharma IncLYEL | COM NEW | 55083R203 | 4.7 | 0.9% | 337,697 | Unchanged |
Sold out: 1 position
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Artiva Biotherapeutics IncARTV | COM | 04317A107 | 0.0 | 0.0% | 0 | Sold out−531,337 |
Source: SEC EDGAR, Form 13F-HR, accession 0000905148-26-003741 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.